

Benztropine (mesylate)

Catalog No: tcsc2733



Available Sizes

Size: 1g



Specifications

CAS No:

132-17-2

Formula:

$C_{22}H_{29}NO_4S$

Pathway:

Neuronal Signaling;GPCR/G Protein

Target:

mAChR;mAChR

Purity / Grade:

>98%

Solubility:

H₂O : ≥ 200 mg/mL (495.61 mM)

Alternative Names:

Benzatropine mesylate;Benzotropine mesylate;Benztropine methanesulfonate

Observed Molecular Weight:

403.54

Product Description


Benzotropine is a centrally-acting, antimuscarinic agent used as an adjunct in the treatment of Parkinson's disease.

Target: mAChR

Benzotropine is a centrally-acting, antimuscarinic agent used as an adjunct in the treatment of Parkinson's disease. It may also be

used to treat extrapyramidal reactions, such as dystonia and Parkinsonism, caused by antipsychotics. Symptoms of Parkinson's disease and extrapyramidal reactions arise from decreases in dopaminergic activity which creates an imbalance between dopaminergic and cholinergic activity. Anticholinergic therapy is thought to aid in restoring this balance leading to relief of symptoms. In addition to its anticholinergic effects, benztropine also inhibits the reuptake of dopamine at nerve terminals via the dopamine transporter. Benztropine also produces antagonistic effects at the histamine H1 receptor [1, 2].

Benztropine (BZT) and its analogues inhibit dopamine uptake and bind with moderate to high affinity to the dopamine transporter (DAT). BZT analogues also exhibit varied binding affinities for muscarinic M(1) and histamine H(1) receptors. The BZT analogues showed a wide range of histamine H(1) receptor ($K(i)=16-37,600$ nM) and DAT ($K(i)=8.5-6370$ nM) binding affinities [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!